Survodutide

What is Survodutide?

Survodutide is an investigational dual glucagon receptor (GCGR) and GLP-1 receptor (GLP-1R) agonist licensed to Boehringer Ingelheim from Zealand Pharma, with Boehringer solely responsible for global development and commercialization. The molecule is derived from the natural gut hormone oxyntomodulin and activates both the glucagon and GLP-1 receptors. The obesity Phase 3 evidence is now peer-reviewed: SYNCHRONIZE-1 (le Roux, Wharton, Kaplan et al., NEJM 7 June 2026) randomized 725 adults with obesity or overweight without type 2 diabetes to weekly subcutaneous survodutide at 3.6 mg or 6.0 mg or placebo for 76 weeks. Under the primary treatment-regimen estimand, mean body-weight reduction was -12.2% at 3.6 mg (95% CI -13.6 to -10.8) and -13.0% at 6.0 mg (95% CI -14.4 to -11.6) versus -5.4% on placebo; ≥5% weight loss occurred in 72.6% (3.6 mg), 71.9% (6.0 mg), and 46.3% (placebo). The near-identical response at 3.6 mg and 6.0 mg — with meaningfully higher GI adverse-event burden at the top dose (89.7% vs 80.9% vs 47.9% placebo) — is a prescriber-relevant nuance and is the strongest empirical answer yet to how much additional benefit escalation to 6.0 mg buys. The companion SYNCHRONIZE-MASLD Phase 3 trial (Kaplan, Sanyal, et al., Nature Medicine, same date) randomized 216 adults with obesity and at-risk MASLD 2:1 to survodutide 6.0 mg or placebo for 48 weeks and met both co-primary endpoints — 84.2% vs 24.3% achieved ≥30% MRI-PDFF liver-fat reduction (efficacy estimand; 68.5% vs 28.6% treatment-regimen) and mean weight change was -12.2% vs -1.0% (efficacy; -8.7% vs -1.4% treatment-regimen). Survodutide carries FDA Fast Track designation (May 2021) and Breakthrough Therapy designation (September 2024) for non-cirrhotic MASH with stage 2 or 3 fibrosis, EMA PRIME scheme acceptance (November 2023), and Breakthrough Therapy designations from China's NMPA (June 2024) and Taiwan FDA (September 2024). It is not yet approved by any regulator. Additional Phase 3 readouts (SYNCHRONIZE-2 in T2D, SYNCHRONIZE-CVOT, SYNCHRONIZE-JP, SYNCHRONIZE-CN) and the LIVERAGE / LIVERAGE-Cirrhosis MASH trials are expected through 2026–2027.

What Survodutide Is Investigated For

Survodutide is being developed for obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH), and as of mid-2026 the strongest evidence is the pair of Phase 3 publications that landed in early June 2026. SYNCHRONIZE-1 (le Roux, Wharton, Kaplan et al., NEJM 7 June 2026) randomized 725 adults with obesity or overweight without type 2 diabetes to weekly subcutaneous survodutide at 3.6 mg, 6.0 mg, or placebo for 76 weeks. Under the primary treatment-regimen estimand, mean body-weight reduction was -12.2% at 3.6 mg (95% CI -13.6 to -10.8) and -13.0% at 6.0 mg (95% CI -14.4 to -11.6) versus -5.4% on placebo; ≥5% weight loss occurred in 72.6%, 71.9%, and 46.3% respectively (all p<0.001). The efficacy-estimand pooled figure — the number initially reported in the April 2026 press release — is 16.6%, the more idealized 'if you stayed on drug' analysis. A prescriber-relevant nuance: the 3.6 mg dose achieved essentially the same weight loss as 6.0 mg while carrying substantially less GI adverse-event burden (80.9% vs 89.7% GI AEs vs 47.9% on placebo). SYNCHRONIZE-MASLD (Kaplan, Sanyal et al., Nature Medicine, same publication date) randomized 216 adults with obesity and at-risk MASLD 2:1 to survodutide 6.0 mg or placebo for 48 weeks and met both co-primary endpoints: 84.2% vs 24.3% achieved ≥30% MRI-PDFF liver-fat reduction (efficacy estimand; 68.5% vs 28.6% treatment-regimen), and mean weight change was -12.2% vs -1.0% efficacy / -8.7% vs -1.4% treatment-regimen. Together these are the first peer-reviewed Phase 3 datasets for both the obesity and MASLD indications and mark the transition from press-release to publication-quality evidence. Phase 2 evidence remains foundational context: 14.9% mean (up to 18.7% in completers) at 46 weeks on 4.8 mg weekly in obesity, and 62% MASH resolution / 36% fibrosis improvement at 4.8 mg over 48 weeks in the Phase 2 NEJM MASH trial. Honest caveats remain: SYNCHRONIZE-2 (T2D), SYNCHRONIZE-CVOT, SYNCHRONIZE-JP, and SYNCHRONIZE-CN are still in follow-up, and the LIVERAGE and LIVERAGE-Cirrhosis Phase 3 MASH trials are enrolling. No randomized head-to-head data versus tirzepatide, semaglutide, or retatrutide exist. The gastrointestinal tolerability signal — mild-to-moderate, concentrated during dose escalation, but affecting a large majority of treated participants — is the dominant clinical trade-off, and whether the near-identical efficacy of 3.6 mg vs 6.0 mg leads regulators or prescribers toward the lower dose as the default is a real question for the eventual label.

History & Discovery

Survodutide (BI 456906) originated as a Zealand Pharma peptide engineered on an oxyntomodulin backbone — oxyntomodulin is a naturally occurring post-translational product of the proglucagon gene that intrinsically activates both the GLP-1 and glucagon receptors, and it has been the starting point for several modern dual-agonist programs. Zealand partnered the molecule with Boehringer Ingelheim in 2011, and Boehringer took operational control of clinical development while Zealand retained royalty rights. Early Phase 1 and Phase 2 work through the late 2010s and early 2020s established dose-dependent weight loss and a distinctive liver-targeted efficacy signal that distinguished it from pure GLP-1 agonists. The 2024 Phase 2 readouts in Lancet Diabetes & Endocrinology (obesity) and the New England Journal of Medicine (MASH/fibrosis) substantially raised the molecule's profile, positioning it as a serious late-stage contender in the incretin class. Regulatory recognition for the MASH indication accumulated through the early 2020s: the FDA granted Fast Track designation in May 2021, the EMA admitted survodutide to its PRIME scheme in November 2023, and three additional regulators awarded Breakthrough-class designations in 2024 — China's NMPA in June 2024, the U.S. FDA in September 2024, and Taiwan's FDA in September 2024. These designations marked survodutide as a serious MASH contender alongside the broader incretin class. The inflection point for the obesity indication arrived in two stages. On April 28, 2026, Boehringer Ingelheim announced positive Phase 3 SYNCHRONIZE-1 topline results. Six weeks later, on June 7, 2026, the full peer-reviewed publication appeared simultaneously in the New England Journal of Medicine (SYNCHRONIZE-1, le Roux et al.) and Nature Medicine (SYNCHRONIZE-MASLD, Kaplan/Sanyal et al.). The NEJM paper reported that 725 adults with obesity or overweight without type 2 diabetes on weekly subcutaneous survodutide at 3.6 mg or 6.0 mg for 76 weeks achieved treatment-regimen-estimand mean body-weight reductions of -12.2% (3.6 mg) and -13.0% (6.0 mg) versus -5.4% on placebo, with ≥5% weight loss in 72.6% / 71.9% / 46.3% of the three arms. The efficacy-estimand pooled figure — the 16.6% number that first appeared in the April topline — is the more idealized 'if you stayed on drug' analysis. Notably, the 3.6 mg and 6.0 mg doses produced essentially identical weight loss while carrying meaningfully different GI adverse-event burden (80.9% vs 89.7%), which is a real signal that the lower dose may be the pragmatic default. The Nature Medicine paper reported the SYNCHRONIZE-MASLD trial: 216 adults with obesity and at-risk MASLD randomized 2:1 to survodutide 6.0 mg vs placebo for 48 weeks, both co-primary endpoints met (84.2% vs 24.3% ≥30% MRI-PDFF liver-fat reduction; -12.2% vs -1.0% weight change, both efficacy estimand), providing the first peer-reviewed Phase 3 evidence for the MASLD/MASH indication and complementing the biopsy-based LIVERAGE program still in follow-up. The SYNCHRONIZE program is now broader than originally announced. Beyond SYNCHRONIZE-1 and the previously described SYNCHRONIZE-2 (obesity with T2D) and SYNCHRONIZE-CVOT (cardiovascular outcomes, baseline characteristics published in JACC Heart Failure November 2025), Boehringer is running SYNCHRONIZE-MASLD (obesity with confirmed or presumed MASH), SYNCHRONIZE-JP (Japan), and SYNCHRONIZE-CN (China). In parallel, the Phase 3 MASH-specific program comprises LIVERAGE (~1,800 adults with MASH and stage 2 or 3 fibrosis, NCT06632444) and LIVERAGE-Cirrhosis (~1,590 adults with compensated MASH cirrhosis, fibrosis stage 4, NCT06632457). A 2026 Molecular Metabolism paper extended the mechanistic story by showing that survodutide acts through circumventricular organs in the brain to activate neuronal regions associated with appetite regulation, reinforcing that the GLP-1 arm of the dual mechanism reaches central feeding circuits. Recent network meta-analyses have begun positioning survodutide and other GCGR agonists comparatively against pure GLP-1s and against the MASH-specific therapy resmetirom, though the definitive head-to-head comparisons against tirzepatide, retatrutide, and semaglutide await dedicated trials. A 2026 network meta-analysis in J Transl Med (Sun et al., 13 RCTs, n=3,871) ranked survodutide 6 mg/week highest by SUCRA (92.0%) for NASH resolution without worsening of fibrosis in MASLD patients at fibrosis stages F1-F3, ahead of tirzepatide 15 mg and resmetirom. The SYNCHRONIZE-JP baseline paper (Yokote et al., Diabetes Obes Metab 2026) reported 274 enrolled Japanese adults with obesity disease (mean BMI 33.2 kg/m², 24.1% with T2D), providing the enrollment context for the Japan-specific efficacy readout. Beyond survodutide, Boehringer has signaled a broader metabolic-health pipeline including a triple GLP-1/GIP/NPY2 receptor agonist peptide (BI 3034701) entering Phase 2 in mid-2026.

How It Works

Survodutide activates two hormone receptors simultaneously: GLP-1 receptors reduce appetite and slow gastric emptying, while glucagon receptors tell your liver to burn more fat and increase overall energy expenditure. This two-pronged approach produces both weight loss and direct liver fat reduction.

Survodutide is a synthetic, long-acting unimolecular peptide derived from oxyntomodulin with dual agonist activity at GCGR and GLP-1R (EC50 ~8 nM and ~1 nM respectively, indicating greater potency at GLP-1R). GLP-1R activation suppresses appetite through hypothalamic and brainstem circuits and slows gastric emptying. GCGR activation increases hepatic fatty acid oxidation, energy expenditure, and thermogenesis while directly reducing hepatic steatosis. The glucagon-mediated liver effects are particularly significant for MASH, where survodutide achieved histologic improvement in fibrosis and steatohepatitis resolution rates substantially exceeding placebo. The complementary mechanisms — reduced energy intake via GLP-1 plus increased energy expenditure and hepatic fat clearance via glucagon — may produce superior metabolic outcomes relative to GLP-1 mono-agonists. A 2026 post hoc analysis of two Phase 2 trials (Ekinci et al., Diabetes Obes Metab 2026) reported that survodutide significantly increased HOMA-β and reduced HOMA-IR, glucagon, and fasting plasma glucose in adults with type 2 diabetes on metformin, with the beta-cell and insulin-sensitivity improvements largely independent of body-weight change — suggesting a metabolic effect that is not purely secondary to weight loss.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Survodutide:

• 01Phase 3 head-to-head data — SYNCHRONIZE-1 and SYNCHRONIZE-MASLD have now published in NEJM and Nature Medicine respectively (7 June 2026), but head-to-head randomized comparisons against tirzepatide, retatrutide, semaglutide 2.4 mg, or CagriSema have not been run, and cross-trial comparisons across different populations, durations, and estimands remain unreliable.
• 02Cardiovascular outcomes — SYNCHRONIZE-CVOT is designed to test MACE reduction; until it reports, survodutide's cardiovascular profile is inferred from class effects rather than directly established.
• 03Durable MASH and fibrosis outcomes — SYNCHRONIZE-MASLD Phase 3 (48-week imaging endpoints, Nat Med 2026) established robust MRI-PDFF liver-fat reduction, and Phase 2 biopsy data showed 62% MASH resolution and 36% fibrosis improvement. The biopsy-based LIVERAGE (n≈1,800, F2-F3 fibrosis) and LIVERAGE-Cirrhosis (n≈1,590, F4) Phase 3 trials are the definitive tests of durable histologic and clinical-outcome benefit; both are still enrolling or in follow-up.
• 04Optimal patient selection — whether survodutide's dual mechanism confers specific advantage in patients with high liver fat, high baseline BMI, or metabolic syndrome relative to GLP-1-only agents is not yet established.
• 05Tolerability versus efficacy trade-off — the higher GI discontinuation rate observed in Phase 2 (~25% at top dose) needs Phase 3 confirmation with the refined titration schedules being tested.
• 06Long-term effects of chronic glucagon-receptor agonism on hepatic glucose output, cardiac muscle, and blood pressure — areas where glucagon biology has historically raised questions that pure GLP-1s avoid.

Forms & Administration

Weekly SC injection. Phase 2 doses: 0.6-4.8mg weekly (obesity); 2.4-6.0mg weekly (MASH). Phase 3 testing doses up to 3.6mg and 6.0mg weekly. Dose titration protocol with 20-24 week escalation phase. All injectable peptides should only be administered under the guidance of a qualified healthcare provider. Never self-administer without clinician oversight.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

Survodutide is not FDA-approved for any indication as of the site's current revision. The doses and schedules above reflect published trial protocols and are not prescriptions. Any access outside of enrollment in a registered clinical trial is not legitimate as of this date.

Timeline of Effects

Common Questions

Who Survodutide Is NOT For

Drug & Supplement Interactions

No FDA-labeled drug interaction profile exists for survodutide because the drug is not approved. The interaction framework is therefore extrapolated from the GLP-1 and glucagon classes. The two most clinically relevant domains are hypoglycemia risk when combined with insulin or sulfonylureas — where downward titration of the concomitant agent will almost certainly be required if survodutide reaches market — and altered oral drug absorption secondary to delayed gastric emptying, which applies to narrow-therapeutic-index agents including warfarin, levothyroxine, and oral antiepileptics. The glucagon-receptor component adds a theoretical layer not present with pure GLP-1s: glucagon raises hepatic glucose output, which could interact with concomitant antidiabetic regimens in ways distinct from semaglutide or tirzepatide. How this translates clinically in Phase 3 populations — particularly older patients with T2D on complex regimens — is an active area of SYNCHRONIZE-2 analysis.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions